Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $933238 | $631500 | $2M | $23258 | $5M | — | — |
| Enterprise Value | $15M | $14M | $-1885324 | $4M | $9M | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — |
| P/S Ratio | 3.62 | 2.45 | 1.91 | 0.01 | 1.89 | — | — |
| P/B Ratio | — | — | 0.37 | — | 0.18 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 55.66 | -2.25 | 1.82 | 3.29 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -60.5% | -60.5% | 24.9% | 5.2% | 124.8% | -1725.1% | 12.3% |
| Operating Margin | -1931.0% | -1931.0% | -523.8% | -465.3% | -770.2% | -6203.4% | -80787.3% |
| Net Profit Margin | -17690.2% | -17690.2% | -489.6% | -1494.2% | -445.0% | -19625.9% | -111569.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | -1830.0% | -279.8% | -94.4% | — | — |
| ROA | -647.1% | -647.1% | -48.9% | -134.9% | -49.6% | -132.0% | -53.8% |
| ROIC | -295.1% | -295.1% | -748.9% | -49.2% | -87.9% | -48.5% | — |
| ROCE | -233.3% | -233.3% | -297.6% | -71.0% | -137.1% | -389.1% | -107.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.08 | — | 0.14 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.82 | — | 0.14 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -50.20 | -50.20 | -31.65 | -125.24 | -70.41 | -234.39 | -2.57 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.58 | 0.58 | 1.39 | 0.18 | 0.41 | 0.48 | 0.05 |
| Quick Ratio | 0.58 | 0.58 | 1.39 | 0.05 | 0.21 | 0.48 | 0.05 |
| Cash Ratio | 0.08 | 0.08 | 1.06 | 0.01 | 0.05 | 0.42 | 0.00 |
| Asset Turnover | — | 0.04 | 0.11 | 0.24 | 0.07 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | 1.59 | 0.35 | — | 2.96 |
| Days Sales Outstanding | — | 1980.01 | 358.63 | 48.08 | 172.16 | 2135.12 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $68941 | $16672 | $11 | $693 | $578 | $578 |
Imminent insolvency and dilution
According to recent market data, Akanda's price-to-sales ratio of 3.62 appears disconnected from its fundamental decline, suggesting that investors are pricing the stock as a speculative shell rather than a viable operating entity within the specialty pharmaceutical sector.
The lack of meaningful P/E or EV/EBITDA multiples underscores the absence of positive earnings or operational cash flow to support traditional valuation models. This valuation suggests that the market is assigning value primarily to the company's regulatory licenses rather than its current, severely diminished revenue-generating capacity.
Based on reported figures, Akanda's ROIC has plummeted to -192.2% in 2025Q4, indicating that the company is not only failing to generate returns on invested capital but is actively destroying value through its current operational and administrative cost structure.
The consistent decay in return metrics over the last ten quarters highlights a fundamental inability to deploy capital effectively in the UK medical cannabis market. This trend suggests that the company's historical investments have failed to yield a sustainable competitive advantage or a path toward profitability.
As reported in financial statements, Akanda's DSO reached an alarming 423 days in 2025Q4, which indicates a severe breakdown in the company's ability to collect receivables and manage its customer-facing credit terms effectively compared to industry norms.
The extreme volatility in the cash conversion cycle suggests that the company lacks the leverage to manage its supplier and customer relationships efficiently. This inefficiency appears to be a structural symptom of the firm's broader operational distress and lack of scale.
Based on the most recent quarterly data, the current ratio of 0.58 indicates that Akanda's short-term assets are insufficient to cover its immediate liabilities, leaving the company in a highly vulnerable position under any scenario of continued operational stress.
The rapid decline in the quick ratio over the observed period confirms that the company has little to no margin for error in its liquidity management. Investors should monitor the company's ability to secure external financing, as the current cash position appears inadequate to sustain operations.
As indicated by the company's financial history, the price-to-sales ratio is the most commonly misapplied metric for Akanda, as it obscures the reality that the firm's revenue is currently insufficient to cover its fixed regulatory and administrative overhead costs.
Using revenue multiples for a company with negative gross margins is misleading because it ignores the fact that every additional dollar of sales may actually increase the company's net loss. Analysts should instead focus on the cash burn rate and the remaining runway to assess the company's survival probability.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AKAN stock.
Akanda Corp.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Akanda Corp. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Akanda Corp. has -60.5% gross margin and -1931.0% operating margin.